Acid suppressants in Cardiac Patients: Sneak Peak of Clinical Guidelines
Cardiovascular diseases (CVD) encompass a range of congenital or acquired pathological conditions that affect the structure or function of the heart, commonly, coronary artery disease (CAD), arrhythmia, myocardial infarction, cardiomyopathy, and peripheral artery disease.
In most patients, thrombus formation due to platelet activation and aggregation is the initial mechanism that ultimately leads to coronary artery thrombosis and further CV complications. This forms the basis for the use of dual antiplatelet therapy (DAPT) with aspirin and an oral P2Y12 inhibitor (Clopidogrel, Prasugrel), which is regarded to be the mainstay of antithrombotic therapy after MI and/or PCI. (1)